Jonathan Alexander Chatzkel

Dr. Jonathan Alexander Chatzkel


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
TOTemitope Ogunmola
Temitope Ogunmola
ZJZeng Jin
Zeng Jin
JKJeremy Kleberg
Jeremy Kleberg
TTTanzia Islam Tithi
Tanzia Islam Tithi
SASeyedehalaleh Anvar
Seyedehalaleh Anvar
WZWeizhou Zhang
Weizhou Zhang
Renal cell carcinoma (RCC), particularly the clear cell subtype, is a solid tumor characterized by a high degree of immune cell infiltration, progressive immune dysfunction, and favorable response to immune checkpoint inhibitors (ICIs). Dual checkpoint inhibition or single-agent ICIs with anti-angiogenic therapies have become the standard of care in the treatment of advanced and metastatic RCCs. Locally advanced and oligometastatic RCCs are distinct clinical categories that are characterized by local invasion and initially limited metastatic spread, respectively, with different therapeutic responses and prognoses compared to either localized or advanced diseases. Herein, we summarize the biology, treatment, and molecular profiling of RCCs, providing an update on the clinical trials pertaining to cancer patients with locally advanced and oligometastatic RCC. We also discuss molecular features that could contribute to a better understanding of the tumor biology driving locally advanced and oligometastatic RCC.

7 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Belén Mora-GarijoBelén Mora-Garijo
Belén Mora-Garijo
SRSyed Nahiyaan Rahman
Syed Nahiyaan Rahman
XXXu Xu
Xu Xu
JCJonathan Alexander Chatzkel
Jonathan Alexander Chatzkel
GGG. Daniel Grass
G. Daniel Grass
Roger LiRoger Li
Roger Li
Histological subtypes of bladder cancer are generally associated with more aggressive disease, higher stage at presentation, and worse prognosis compared to conventional urothelial carcinoma. Recent updates in classification systems have further refined the distinction between true histologic subtypes and divergent differentiation, underscoring the complexity of these tumors. Emerging molecular profiling studies have identified subtype-specific genomic alterations, including ERBB2 amplification in micropapillary subtype carcinoma, CDH1 loss in plasmacytoid subtype carcinoma, and TP53 and RB1 co-alterations in neuroendocrine bladder cancer, which may contribute to differences in tumor biology and therapeutic response. Despite these advances, the histological subtypes of bladder cancer remain underrepresented in prospective clinical trials, leading to significant gaps in evidence-based management. Treatment responses vary widely across subtypes, with some demonstrating sensitivity to platinum-based chemotherapy or immunotherapy, while others appear less responsive to conventional approaches. This review summarizes the current understanding of the epidemiology, molecular landscape, and clinical behavior of major bladder cancer subtypes and highlights emerging opportunities for personalized treatment strategies, biomarker-driven therapies, and more inclusive clinical trial design to improve outcomes in this high-risk population.